Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Isoelectric focusing variant thyroxine-binding globulin in American blacks: increased heat lability and reduced serum concentration.
Multiple hats for natural killers.
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).
Arctic Regions
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.
See All 7 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood. 2008 Aug 01; 112(3):741-9.
View in:
PubMed
subject areas
Age Factors
Female
Genetic Predisposition to Disease
Genotype
Humans
Leukemia, Myeloid
Male
Neoplasms, Second Primary
Polymorphism, Genetic
Proto-Oncogene Proteins c-mdm2
Risk Factors
Sex Factors
Tumor Suppressor Protein p53
authors with profiles
Richard A. Larson
Dezheng Huo